A Phase 1b/2 study evaluating the safety and efficacy of MPDL3280A in combination with either OBINUTUZUMAB plus BENDAMUSTINE or OBINUTUZUMAB plus chop in patients with follicular lymphoma or diffuse large b-cell lymphoma

Project: Research

Project Description

NMA Reference Number: HREC/15/HNE/343.
SSA Reference Number: SSA/16/MonH/82.
Monash Health HREC Ref: 16140X
StatusActive
Effective start/end date2/08/19 → 1/08/24
View all
View less

Keywords

  • Clinical trial
  • treatment efficacy
  • lymphoma
  • phase 1 and 2 study